Dopaminergic supersensitivity in parkinsonism.
D000368:Aged; D001593:Benzyl Compounds / Q000008:administration & dosage; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry / Q000187:drug effects; D004298:Dopamine / Q000032:analysis / Q000378:metabolism*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage; D006897:Hydroxyindoleacetic Acid / Q000032:analysis; D007980:Levodopa / Q000009:adverse effects* / Q000494:pharmacology; D009410:Nerve Degeneration; D009638:Norepinephrine / Q000032:analysis; D010300:Parkinson Disease / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced / Q000209:etiology*; D012701:Serotonin / Q000032:analysis; D014364:Tryptophan / Q000008:administration & dosage / Q000032:analysis; D014443:Tyrosine / Q000032:analysis
D001593:Benzyl Compounds; D006834:Hydrazines; D012701:Serotonin; D014443:Tyrosine; D007980:Levodopa; D006897:Hydroxyindoleacetic Acid; D014364:Tryptophan; D004298:Dopamine; D009638:Norepinephrine